Академический Документы
Профессиональный Документы
Культура Документы
Historia clnica.
Datos de filiacion
Nombre y apellido: HC
Edad: 60 aos
FN: 20/05/56
LN: As
Procedencia: Fdo. De la Mora
Escolaridad: terciaria
Ocupacin: jubilado
Religin: catlico
Estado civil: casado
Hijos: 3
MC: cambios en la conducta
98.
tto desde hace 5 aos con tto regula con levodopa 1000 mg/da,
clonazepam 3mg/da hipertenso desde los 45 aos en tto regular con
enalapril 20 mg/da en 2 tomas, niega DM, alergias y asma. Es evaluado
por la guardia de clnica medica que, estabiliza PA y solicita laboratorio
completo y tac de crneo simple y solicita IC con el servicio de enlace.
Imp Dx: trastorno psictico debido a otra afeccin medica con delirios
probable.
descartar organicidad.
IC con neurologa y control evolutivo por psiquiatra de enlace.
Dependiendo de la contribucin de
FACTORES ENDGENOS
La corteza prefrontal juega un papel muy importante en el control de las
FACTORES EXOGENOS
El factor exgeno ms importante en el desarrollo de la
TRATAMIENTO DE LA
PSICOSIS
CLOZAPINA
El primer atipsictico atpico que fue aprobado es la clozapina, derivado de una
se encontr que la clozapina es segura y benfica para aliviar la psicosis sin afectar
la funcin motora (15,16)
QUETIAPINA
La quetiapina es un frmaco estructuralmente similar a la clozapina, acta
OLANZAPINA
es un frmaco que acta como antagonista del receptor serotonrgico 5-
RISPERIDONA
Tiene una fuerte afinidad por los receptores 5-HT-2A as como por los receptores
D2. Tiene un efecto antagnico dbil por los receptores adrenrgicos 1 y por los
receptores histaminrgicos, sin mostrar afinidad por los muscarnicos.
PIMAVANSERINA
De la pimavaserina, un agonista inverso selectivo del receptor
5HTA2
BIBLIOGRAFIA
1. Jenner P, Olanow Cw. Understanding cell death in Parkinson's disease.Ann Neurol1998; 44(3 Suppl 1):S72-84.
2. Jellinger Ka. Neuropathological correlates of mental dysfunction in Parkinson's disease: an update.In: Mental dysfunctions
3. Klein C, Kompf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson's disease.J
Neurol1997; 244(6):371-7.
4. Sanchez-Ramos Jr, Ortoll R, Paulson Gw. Visual hallucinations associated with Parkinson disease.Arch Neurol1996;
53(12):1265-8.
5. Aarsland D, Larsen Jp, Cummins Jl, LAAKE K. Prevalence and clinical correlates of psychotic symptoms in Parkinson
6. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian
patients.Neurology1998; 51(3):811-4.
7. Wolters EC, Psychiatric complications in the treatment of Parkinson's disease.Adv Neurol2001; 86: 385-93.
8. Wolters Ec, Francot Cmje. Mental dysfunctions in Parkinson's disease.Parkinsonism Related Disord1998; 4107-112.
9. Everitt BJ, Robbins TW. Central cholinergic systems and cognition.Annu Rev Psychol1997; 48:649-84.
10. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis.Brain Res Rev1997; 23(1-
2):28-46.
11. Perry EK, Curtis M, Dick DJ. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with
12. Tiraboschi P, Hansen LA, Alford M. Cholinergic dysfunction in diseases with Lewy bodies.Neurology2000;54(2):407-11.
13. Haase Hj, Janssen Paj:The action of neuroleptic drugs: a psychiatric neurologic and pharmacological investigation
1965.
15. The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in
16. The French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson's
disease.Lancet1999; 353(9169):2041-2.
17. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of
18. Targum Sd, Abbott Jl. Efficacy of quetiapine in Parkinson's patients with psychosisJ Clin
Psychopharmacol2000; 20(1):54-60.
19. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans Pl. Olanzapine in the treatment of
20. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's
diseaseNeurology1998; 50(4):1195-6.
21. Graham JM, Sussman JD, Ford KS, Sagar HJ: Olanzapine in the treatment of hallucinosis in idiopathic
22. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine.Mov
Disord.1999;14(6):1014-6.
23. Ondo WG, Levy JK, Vuong KG, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-
24. Breier A, Sutton VK, Feldman PD. Olanzapine in the treatment of dopamimetic-induced psychosis
26. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism.Mov
Disord2000;15(2):301-4.
27. Mohr E, Mendis T, Hildebrand K, DE Deyn PP. Risperidone in the treatment of dopamine-induced
28. Workman Rh, Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and
29. Ellis T, Cudkowicz Me, Sexton Pm, Growdon Jh. Clozapine and risperidone treatment of psychosis in
30. Cummings J, et al.:Pimavanserin for patients with Parkinsons disease psychosis: a randomized,
31. Hacksell U, et al.:On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for
32. Ballard C, et al.:Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse
Events in People With Parkinson Disease Psychosis.Journal of the American Medical Directors Association,
e-pub (2015).
33. Meltzer HY, et al.:Pimavanserin, a serotonin 2A receptor inverse agonist for the treatment of
34. Meltzer HY, et al.:Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy
and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison
with reference dose risperidone, 6 mg/day.Schizophrenia Research, 141, 144-152 (2012).
35.